AzTrials
AzTrials

Comprehensive Geriatric AssessmentCGACDM - OlderNCT07033871

Comprehensive Geriatric Assessment in Chronic Disease Management for Older Adults in China: A Registry Study (CGACDM - Older Adults in China)

An observational study of Comprehensive Geriatric Assessment and Chronic Disease Management, run by Henan Provincial People's Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

With the continuous development of China's economy and the improvement of medical standards, the life expectancy of the Chinese population has significantly increased. Against the backdrop of accelerating aging in China, the incidence of age-related chronic non-communicable diseases (NCDs), such as cardiovascular and… Read more about this study

Who is it for?
Ages 60 years and olderHealthy volunteers can take part
What is being tested?
comprehensive geriatric assessment
How many people
1,000 participants
Where
No sites listed yet
Study dates
1 Jul 2025to 1 May 2030
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population consisted of patients with chronic diseases in the elderly who underwent comprehensive geriatric assessment and management. Chronic diseases in the elderly included but were not limited to chronic heart failure, chronic obstructive pulmonary disease, cognitive dysfunction, and so on.

Who may be able to join

  • 1. Aged 60 years or older 2. Diagnosed with chronic diseases in the circulatory, respiratory, digestive, nervous, or endocrine systems, consistent with corresponding disease diagnostic criteria; 3. Availability of complete medical records; 4. Clear consciousness and ability to independently answer questions; 5. Signed informed consent form.

Who cannot join

  • 1. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
  • 2. Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
  • 3. Current participation in a randomised interventional clinical trial.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Yang Xinying Yang Xinying contact

0371-87160164

xinyingyang150@163.com

About this study

With the continuous development of China's economy and the improvement of medical standards, the life expectancy of the Chinese population has significantly increased. Against the backdrop of accelerating aging in China, the incidence of age-related chronic non-communicable diseases (NCDs), such as cardiovascular and cerebrovascular diseases and chronic respiratory diseases, has risen remarkably. These diseases are characterized by multiple comorbidities, high disability rates, and high mortality rates, severely compromising the quality of life of older adults, exacerbating family burdens, and straining healthcare systems. This constitutes one of the major challenges faced by aging societies. Therefore, early detection and intervention of chronic diseases in older adults are critical measures to address population aging.

Comprehensive geriatric assessment (CGA), a core specialty of geriatric medicine, serves as a fundamental framework for the clinical identification of geriatric syndromes and multidisciplinary management. It is emerging as a key pathway to promote "healthy aging." Guided by this premise, this study aims to explore the application value of CGA in managing chronic diseases among older adults, with the goal of achieving full-cycle management for early detection, diagnosis, and treatment of chronic conditions in China's elderly population.

Being tested
comprehensive geriatric assessment
Keywords
Comprehensive Geriatric Assessment, Chronic Disease Management, Older Adults

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • comprehensive geriatric assessmentDiagnostic test

    The comprehensive geriatric assessment (CGA) is a multi dimensional diagnostic process used to determine the medi cal, psychological, and functional capabilities of a frail elderly person to develop a coordinated and integrated plan for treat ment and long-term follow-up.

Study groups in NCT07033871
Study groupRoleWhat they receive
Elderly patients with chronic diseasesThe study population consisted of patients with chronic diseases in the elderly who underwent comprehensive geriatric assessment and management. Chronic diseases in the elderly included but were not limited to chronic heart failure, chronic obstructive pulmonary disease, cognitive dysfunction, and so on. We compared various biochemical indexes, cardiac function indexes, quality of life, and the occurrence of long-term adverse events before and after the comprehensive geriatric assessment and management.
Receives: Diagnostic Test: comprehensive geriatric assessment
Healthy elderly populationThe control group was composed of elderly subjects without evidence of chronic diseases. Chronic diseases was excluded by performing a complete medical history, a comprehensive physical examination, and an echocardiogram.
Receives: Diagnostic Test: comprehensive geriatric assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major adverse events (MAE)

    Major adverse events (MAE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke, etc.

    Measured: These data is collected during follow-up visit at 3/6/12/24/36 months after discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2025
  2. Study start1 Jul 2025 (estimated)
  3. Primary completion1 May 2030 (estimated)
  4. Study completion1 May 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07033871
Sponsor's protocol ID
HenanPPH-CGA
Acronym
CGACDM - Older
Status last verified
May 2025
First submitted
26 May 2025
Last updated
24 Jun 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Comprehensive Geriatric Assessment and Chronic Disease Management, run by Henan Provincial People's Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yang Xinying Yang Xinying (0371-87160164, xinyingyang150@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major adverse events (MAE) (time frame: These data is collected during follow-up visit at 3/6/12/24/36 months after discharge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in